Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Johnson and Johnson
Express Scripts
AstraZeneca
Harvard Business School

Last Updated: June 29, 2022

CLINICAL TRIALS PROFILE FOR CAPMATINIB HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Capmatinib Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01610336 ↗ A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment Completed Novartis Pharmaceuticals Phase 2 2012-04-05 This study assessed the safety and efficacy of escalating doses INC280 when added to gefitinib in patients with lung cancer that were known to have dysregulation of the c-MET pathway and who had failed after benefiting on a prior treatment with either gefitinib or erlotinib.
NCT02587650 ↗ Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Terminated Adil Daud Phase 2 2015-03-26 This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02587650 ↗ Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Terminated University of California, San Francisco Phase 2 2015-03-26 This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Capmatinib Hydrochloride

Condition Name

Condition Name for Capmatinib Hydrochloride
Intervention Trials
Carcinoma, Non-Small-Cell Lung 4
Non-small Cell Lung Cancer 2
Non-Small Cell Lung Cancer (NSCLC) 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Capmatinib Hydrochloride
Intervention Trials
Carcinoma, Non-Small-Cell Lung 11
Lung Neoplasms 7
Carcinoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Capmatinib Hydrochloride

Trials by Country

Trials by Country for Capmatinib Hydrochloride
Location Trials
Spain 26
United States 19
Italy 17
China 14
Australia 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Capmatinib Hydrochloride
Location Trials
Massachusetts 5
New York 3
California 3
Texas 2
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Capmatinib Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Capmatinib Hydrochloride
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Capmatinib Hydrochloride
Clinical Trial Phase Trials
Recruiting 8
Completed 3
Not yet recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Capmatinib Hydrochloride

Sponsor Name

Sponsor Name for Capmatinib Hydrochloride
Sponsor Trials
Novartis Pharmaceuticals 14
Novartis 2
Assistance Publique - Hôpitaux de Paris 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Capmatinib Hydrochloride
Sponsor Trials
Industry 18
Other 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Express Scripts
Johnson and Johnson
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.